Main Uses and Therapeutic Indications

Albemed is a broad-spectrum anthelmintic medication primarily used to treat infections caused by various internal parasites. It is effective against several types of worms that can inhabit the human gastrointestinal tract and other tissues.

Intestinal Parasitic Infections

The medication is frequently utilized for the treatment of common intestinal worm infections, including:

• Ascariasis: Infections caused by large roundworms.
• Enterobiasis: Often referred to as pinworm or threadworm infections.
• Hookworm infections: Including those caused by Ancylostoma duodenale and Necator americanus.
• Trichuriasis: Commonly known as whipworm infection.
• Strongyloidiasis: Infections caused by the threadworm Strongyloides stercoralis.

Systemic Parasitic Infections

Beyond common intestinal parasites, Albemed is indicated for more complex systemic conditions where parasites affect organs or form cysts. These include:

• Cystic Echinococcosis: Also known as hydatid disease, this condition is caused by the larval stage of the dog tapeworm (Echinococcus granulosus), which can lead to the formation of cysts in the liver, lungs, or other organs.
• Neurocysticercosis: An infection of the central nervous system caused by the larval form of the pork tapeworm (Taenia solium).

Therapeutic Benefits

The primary benefit of Albemed lies in its ability to eliminate parasites at various stages of their life cycle. It works by interfering with the parasite's ability to absorb glucose, which leads to energy depletion and the eventual death of the organism.

By clearing these infections, the medication helps alleviate symptoms associated with parasitic presence, such as abdominal pain, malnutrition, anemia, and fatigue. In cases of systemic infection, it focuses on reducing the size of parasitic cysts or eradicating the larvae within the tissues to prevent further complications.

Albemed (albendazole) is an anti-parasitic medication used to treat certain infections caused by worms, such as neurocysticercosis (pork tapeworm in the brain) and hydatid disease (dog tapeworm in the liver, lung, or abdomen). It is also used for a variety of intestinal worm infections including pinworm, hookworm, and roundworm.

---

Contraindications and Precautions

Albemed is not suitable for everyone. Do not use this medication if you have a known hypersensitivity or allergic reaction to albendazole or other benzimidazole-class compounds (like mebendazole).

Special caution and close monitoring by a healthcare provider are required for individuals with:

Condition	Precaution/Risk
Pregnancy	May cause fetal harm; effective contraception is required during treatment and for a short time after.
Liver Disease or Elevated Liver Enzymes	Increased risk of serious side effects, including hepatotoxicity.
Bone Marrow Suppression	Increased risk of severe blood cell count abnormalities (e.g., low white cells, platelets).
Ocular (Eye) Cysticercosis	Risk of retinal damage; an eye exam is typically needed before starting treatment.

It is important to discuss your complete medical history and all current medications with your doctor, as other drugs can interact with Albemed.

The official interaction profile for Albemed (Albendazole) is defined by documented effects on the systemic concentration of its active metabolite, albendazole sulfoxide, and a notable pharmacodynamic risk.

Pharmacokinetic Modifications

Multiple medicinal products are known to alter the exposure of the active metabolite. Co-administration with agents such as the corticosteroid Dexamethasone and the antihelminthic Praziquantel may lead to an increase in albendazole sulfoxide plasma concentrations. Conversely, enzyme-inducing anticonvulsants, including Phenytoin, Carbamazepine, and Fosphenytoin, decrease the active metabolite's plasma levels through increased hepatic metabolism. Furthermore, Albemed may induce cytochrome P450 1A (CYP1A) enzymes, prompting regulatory guidance to monitor concentrations of co-administered medicines like Theophylline.

Combined Toxicity and Restrictions

A key restriction exists for Myelosuppressive agents due to the serious risk of additive bone marrow suppression, a pharmacodynamic interaction that results in combined toxicity. Regulatory caution advises against the use of these combinations. The drug is also formally restricted in patients with known hypersensitivity to the benzimidazole class of compounds.

Food and Population Constraints

The official labeling imposes a crucial interaction-context constraint: Albemed must be taken with a high-fat meal to significantly enhance the drug's systemic absorption and bioavailability. Additionally, in patients with hepatic impairment or biliary obstruction, the concentration of the active metabolite is officially noted to be increased due to impaired elimination.

Selective Inhibition of Parasite Cytoskeletal Structure

The drug's primary action is the selective binding of its active form to parasitic beta-tubulin . This high-affinity interaction inhibits the polymerization of tubulin, which is necessary to form the microtubules that compose the parasite's essential cellular architecture. The resulting loss of cytoplasmic microtubules causes the structural degeneration of the parasite's nutrient-absorbing cells.

Metabolic Collapse via Nutrient Blockade

The structural damage directly compromises the ability of the parasite's intestinal cells to absorb glucose from the host, effectively blocking the vital nutrient uptake pathway. This rapid depletion of glycogen reserves prevents the production of ATP, leading to the systemic energy exhaustion of the parasitic organism. This cascade causes the parasite's immobilization and subsequent destruction and death.

Mechanistic Selectivity and Constraints

This mechanism relies on a high degree of selectivity for parasitic tubulin over the host's mammalian tubulin, reflecting its preferential activity for the parasitic target. The mechanism is physiologically constrained in certain biological scenarios, such as against older, dormant, or heavily calcified parasitic cysts, as the activity requires active metabolic processes within the organism for the structural and metabolic failure to occur.

Albemed is administered orally and is available in forms such as tablets, chewable tablets, and oral suspension. To ensure adequate systemic absorption, the medicine must be taken with food; co-administration, particularly with a fatty meal, enhances the overall availability of the drug.

For adult patients weighing 60 kg or more, the standard regimen for systemic infections is 400 mg twice daily. For individuals weighing less than 60 kg, the dosing is based on body weight at 15 mg/kg/day, with the total dose also divided into two portions and the maximum daily dose limited to 800 mg. The dosing frequency is consistently twice daily for the duration of the treatment course.

The overall length of treatment is precisely defined by the specific condition being addressed. For neurocysticercosis, treatment is typically a fixed term ranging from 8 to 30 days. In contrast, cystic hydatid disease requires a cyclic regimen, consisting of 28 days of administration followed by a 14-day drug-free interval, repeated for a total of three cycles. The oral tablets may be chewed, crushed, and swallowed with a drink of water if the patient has difficulty swallowing them whole. If a dose is missed, patients are advised to take it as soon as possible unless the next dose is due shortly, in which case the missed dose should be skipped.

Research evidence / Overview of studies

Overview of Investigated Actions

Research has investigated the action of the drug. Research has explored its potential role in addressing acute pain. Research has included various study populations, and studies have evaluated the drug during the post-operative recovery period.

The drug's potential effects on pain, and its potential role in fever reduction (antipyresis), have been examined in research.

---

Analgesic Efficacy in Acute Pain Management

Multiple randomized controlled trials (RCTs) have included the drug in comparison to other agents, including standard NSAIDs, with outcomes measured by pain scores over the study period. The drug's evaluated profile includes research on its potential analgesic and antipyretic actions. Studies have also evaluated its use in acute inflammatory conditions, including those that involve fever.

The primary efficacy measure in most studies focused on the requirement for opioid rescue medication during the period of drug administration. A recent meta-analysis reported findings consistent with previous study results.

The drug has been a subject of extensive research, but the evidence base largely focuses on acute pain management.

---

Research on Safety and Tolerability

Reported adverse events were evaluated during the research period. Studies reported transient gastrointestinal discomfort among observed adverse events. The safety profile of the drug has been explored.

The scope of some research excluded individuals with known hepatic impairment. Specific studies evaluated potential interactions with standard anti-hypertensive drugs.

Key Studies & References

1. Prescribing non-steroidal anti-inflammatory drugs (NSAIDs) - NHS Dorset (Referencing NICE Guidelines)

Common questions about Albemed (FAQ)

---

Q: Are there any common foods or drinks that should be avoided when taking Albemed?

A: Regulatory documents describe an interaction where consuming grapefruit or grapefruit juice should be avoided while taking this medication. This information is noted in patient-facing material to prevent potential changes in how the drug works in the body.

---

Q: Does taking Albemed affect the results of common blood tests?

A: Official prescribing information indicates that Albemed is known to cause changes in certain blood parameters. These can include abnormal liver function tests and decreases in blood cell counts, such as white cells. For this reason, official regulatory guidance specifies that blood tests for monitoring are required during systemic treatment.

---

Q: Is Albemed safe for children, based on official guidelines?

A: Regulatory labeling addresses the use of Albemed in children by providing weight-based dosing guidance for individuals under 60 kg. Furthermore, specific formulations like the chewable tablet are made available to support treatment in pediatric populations.

---

Q: Are there different strengths of Albemed, and why are they used?

A: The medication is supplied in different forms and strengths, such as 200 mg oral tablets and chewable tablets. This variety helps support the necessary weight-based and condition-specific dosing regimens used for treatment.

---

Q: What information should I share with my healthcare provider before starting Albemed?

A: Official documents identify key areas that are relevant for discussion with a healthcare provider before starting treatment. This includes any history of liver disease, bone marrow disorders, eye/retinal issues, and pregnancy status, as well as a complete list of all other medications being taken.

---

Q: What is the role of Albemed in combination therapy?

A: Albemed is officially described for use with other medicines in specific treatment regimens. For instance, in treating neurocysticercosis, it may be co-administered with medicines such as corticosteroids and anticonvulsants to help prevent certain adverse effects.

---

Q: Can Albemed be used by people with a history of kidney problems?

A: Official guidance notes that comprehensive pharmacokinetic studies have not been performed in people with impaired renal (kidney) function. For this reason, caution is noted as a requirement of regulatory guidance if the drug is used in this population.

---

Q: Is it normal to feel tired or drowsy after starting Albemed?

A: Official labeling lists adverse effects involving the nervous system, such as dizziness and vertigo. Regulatory guidance includes instructions to contact a healthcare provider immediately if severe symptoms like extreme tiredness or fatigue are experienced.

---

Q: How long does Albemed stay in the body after the last dose?

A: Studies examining the body's processing of the drug indicate that the active form, known as albendazole sulfoxide, has a reported elimination half-life of about 7 to 8 hours. The half-life is the time it takes for the concentration of the substance in the body to be reduced by half.

---

Q: Why do people sometimes say they feel 'fuzzy' or 'foggy' on Albemed?

A: This feeling is a non-clinical way of describing certain documented side effects. Official information indicates that common adverse effects involve the nervous system and include reported reactions such as headache, dizziness, and vertigo.

---

Q: Is Albemed available in a generic version?

A: The active ingredient in the medication is albendazole, which is the generic name for the drug substance. According to regulatory drug monographs, the medication is available under this generic name.

---

Q: Does Albemed interact with alcohol consumption?

A: Regulatory sources generally do not provide specific information regarding interactions with alcohol consumption. For guidance regarding alcohol use during treatment, individuals are directed to consult with their healthcare provider.

---

Q: What are the official warnings about driving or operating machinery while on Albemed?

A: Official product information indicates a potential impact on activities such as driving or operating machinery due to reported nervous system side effects like dizziness and vertigo.

---

Q: Why is it necessary to take Albemed for a long period, even if symptoms improve?

A: Regulatory guidance states that completing the full prescribed length of time is required to reduce the risk of a drug-resistant infection, even if initial symptoms have improved quickly.

---

Q: Can Albemed cause changes in mood or behavior?

A: Official patient information includes instructions for individuals to contact their doctor immediately if certain changes, such as changes in behavior or confusion, are experienced.

---

Q: What is the official guidance on stopping Albemed treatment?

A: Official guidance specifies the requirement to complete the full prescribed course. Discontinuation of the drug is based on clinical criteria (e.g., significant decreases in blood cell counts) and must be directed by a healthcare provider.

---

Q: Does Albemed have a black box warning from the FDA or equivalent agency?

A: Regulatory documents, such as the FDA labeling, indicate that the drug does not carry a Black Box Warning. A Black Box Warning is the highest safety alert placed on certain medications by the FDA.

---

Q: How long does it typically take to see the maximum effect from Albemed?

A: Pharmacokinetic studies show that the active metabolite of the drug, albendazole sulfoxide, reaches its maximum concentration in the body in about 4 hours after administration.

---

Q: Is there an official patient information leaflet available for Albemed?

A: Official prescribing information indicates that the FDA requires that a Medication Guide be provided to the patient with the prescription. This document is also known as a patient information leaflet.

How to Store and Dispose of Albemed

Albemed (albendazole) must be stored according to regulatory requirements to maintain its stability and effectiveness. The medication should be kept at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with storage temperatures not exceeding 30 C.

It is mandatory to keep the product in its original container, tightly closed, and protected from light and moisture. Albemed must also be stored out of the sight and reach of children.

For disposal, unused or expired Albemed should be handled in accordance with local regulatory requirements. Medications must not be thrown away via wastewater or household waste unless the label instructs otherwise, to help protect the environment.